---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-22-025278"
form_type: "8-K"
ticker: "PVLA"
cik: "0001583648"
company_name: "PALVELLA THERAPEUTICS, INC."
filed_at: "2022-11-01T23:59:59+00:00"
generated_at: "2026-06-22T18:21:29.280862+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Pieris doses first subject in Phase 1 trial of inhaled CTGF inhibitor PRS-220 for IPF

## Summary
- First subject dosed in Phase 1 dose-escalation study of PRS-220, an inhaled Anticalin protein targeting CTGF.
- Study evaluating safety, tolerability, and PK in healthy volunteers; results expected in 2023.
- IPF affects over 3 million patients worldwide; median survival 3-5 years from diagnosis.
- PRS-220 is the second inhaled respiratory program Pieris has brought into the clinic.
- CEO Stephen Yoder highlights potential for meaningful improvement in quality of life for IPF patients.

## SEC filing metadata
- accession: 0001437749-22-025278
- form_type: 8-K
- ticker: PVLA
- cik: 0001583648
- company_name: PALVELLA THERAPEUTICS, INC.
- filed_at: 2022-11-01T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1583648/000143774922025278/0001437749-22-025278-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1583648/000143774922025278/pirs20221031b_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-22-025278
- JSON: https://secwatch.observer/filing/0001437749-22-025278.json
- Plain text: https://secwatch.observer/filing/0001437749-22-025278.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.